Emily Drabant Conley

Emily has served as Vice President of Business Development for 23andMe since 2010, a position in which she has demonstrated a passion for accelerating clinical progress and improving patient care by disrupting healthcare inefficiencies.

At 23andMe Emily is responsible for setting company strategy, including leveraging and monetizing the firm's innovative database. She oversees business and corporate development as well as alliance management. She has a proven track record of forging groundbreaking partnerships with leaders in pharma, biotech, digital health, big data, retailers, CPG, traditional healthcare, and academia.

Deeply involved in capital strategy, Emily was instrumental in developing 23andMe’s partnership with GlaxoSmithKline which resulted in a $300 million equity investment from GSK.

Prior to 23andMe, Emily spent 10 years conducting research that combined genetics and neuroimaging to understand neuropsychiatric disease. She was a Research Fellow at the National Institute of Mental Health and is a co-author on more than 30 academic publications. She formerly served on the Advisory Board of Lesbians Who Tech, an organization dedicated to increasing diversity representation in the technology industry. She also previously served on the board of the UCSF Alliance Health Project, a clinic which provides services to the LGBT and HIV-affected communities in San Francisco.

Emily received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. She graduated summa cum laude from Vanderbilt University with a B.A. in Psychology and Business.